A B S T R A C T
Background. Connective tissue growth factor (CTGF/CCN2) regulates the signalling of other growth factors and promotes fibrosis. CTGF is increased in mice and humans with peritoneal fibrosis. Inhibition of CTGF has not been examined as a potential therapeutic target for peritoneal fibrosis because systemic CTGF knockout mice die at the perinatal stage. Methods. To study the role of CTGF in peritoneal fibrosis of adult mice, we generated CTGF conditional knockout (cKO) mice by crossing CTGF floxed mice with RosaCreER T2 mice. We administered tamoxifen to Rosa-CTGF cKO mice to delete the CTGF gene throughout the body. We induced peritoneal fibrosis by intraperitoneal injection of chlorhexidine gluconate (CG) in wild-type and Rosa-CTGF cKO mice.
Results. Induction of peritoneal fibrosis in wild-type mice increased CTGF expression and produced severe thickening of the peritoneum. In contrast, CG-treated Rosa-CTGF cKO mice exhibited reduced thickening of the peritoneum. Peritoneal equilibration test revealed that the excessive peritoneal small-solute transport in CG-treated wild-type mice was normalized by CTGF deletion. CG-treated Rosa-CTGF cKO mice exhibited a reduced number of aSMA-, Ki67-, CD31-and MAC-2-positive cells in the peritoneum. Analyses of peritoneal mRNA showed that CG-treated Rosa-CTGF cKO mice exhibited reduced expression of Cd68, Acta2 (aSMA), Pecam1 (CD31) and Vegfa. Conclusions. These results indicate that a deficiency of CTGF can reduce peritoneal thickening and help to maintain peritoneal function by reducing angiogenesis and inflammation in peritoneal fibrosis. These results suggest that CTGF plays an important role in the progression of peritoneal fibrosis.
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I N T R O D U C T I O N
Peritoneal dialysis (PD) is an established method of home dialysis for patients in end-stage renal failure [1] . Although PD has several advantages compared with haemodialysis, functional peritoneal deterioration that results from long-term PD is an obstacle that prevents PD from widespread application for renal replacement therapy [2] . These structural alterations may result in ultrafiltration failure and are potentially implicated in encapsulating peritoneal sclerosis (EPS) [3] , serious problems for patients receiving PD. Ultrafiltration failure is a major complication of PD and is one of the main reasons for its discontinuation [4] .
Many factors can induce peritoneal fibrosis and angiogenesis. Transforming growth factor-b (TGF-b) and vascular endothelial growth factor-A (VEGF-A) are important cytokines implicated in fibrosis and angiogenesis, respectively [5] . Loureiro et al. [6] demonstrated that blocking TGF-b1 in mice could ameliorate peritoneal fibrosis and angiogenesis, improving peritoneal function. However, direct inhibition of systemic TGF-b1 activity may not be desirable in humans given the important role it has in immune system regulation [7] . In this investigation, we focused instead on downstream targets of TGF-b1.
Connective tissue growth factor (CTGF) is a member of the CCN (Cyr61, CTGF and NOV) family of matricellular proteins, and is also designated as CCN2 [8] . CTGF is a downstream mediator of the profibrotic properties of TGF-b. In cultured fibroblasts, CTGF expression is strongly induced by TGF-b1 [9] , and CTGF has multiple functions, including extracellular matrix (ECM) accumulation, cell proliferation, cell adhesion and migration [8] .
In the peritoneum, CTGF is detected in peritoneal dialysate effluent and in human peritoneal mesothelial cells (HPMCs) [10] . CTGF is weakly expressed by mesothelial cells under normal conditions in humans and mice [10, 11] . In human peritoneal biopsy specimens, CTGF mRNA expression in peritoneal membrane is well correlated with the thickness of peritoneal membrane, and is significantly increased in patients with EPS [12, 13] . Advanced glycation end products and glucose degradation products in PD solution upregulate the synthesis of CTGF by HPMC and human peritoneal fibroblasts [14] . For these reasons, blockade of CTGF could be a potential treatment for peritoneal fibrosis. In addition, inhibition or overexpression of CTGF does not influence organ microstructure in many organs at healthy condition in adult mice [15, 16] , suggesting the potential safety to intervene CTGF. However, analysis of CTGF actions in knockout (KO) mice with peritoneal fibrosis has not been reported. Conventional CTGF KO mice die shortly after birth because of respiratory failure caused by skeletal defects [17] . To overcome this problem, we generated drug-inducible CTGF conditional KO (Rosa-CTGF cKO) mice using the Cre-loxP system [15] . In the present study, we used Rosa-CTGF cKO mice to investigate the actions of CTGF in the development of peritoneal fibrosis.
M A T E R I A L S A N D M E T H O D S

Ethics
All animal handling and experimentation was conducted according to the guidelines of the Animal Experimentation Committee of Kyoto University. All experimental protocols were approved by the Animal Experimentation Committee of Kyoto University. This study was approved by the ethics committee on human research of the Graduate School of Medicine, Kyoto University and was conducted in accordance with the Helsinki Declaration.
Patients
Patients who were admitted to Kyoto University Hospital for renal disorders were enrolled under informed consent. The parietal peritoneal samples were taken from the insertion site of a PD catheter located in the lumbar region as biopsies at the beginning or ending of PD.
Experimental animals
We used C57BL/6-Gt (ROSA) 26Sortm9
) mice and Ctgf fl/fl mice as described previously [15] . Tamoxifen-inducible systemic CTGF conditional KO (Rosa-CTGF cKO) mice were generated by mating CTGF , Cre (À)] mice were treated with 0.2 mg/gBW tamoxifen (Sigma Aldrich, St Louis, MO, USA) orally for 3 days at both 3 and 6 weeks of age [15] . Phosphate-buffered saline (PBS)-injected control mice, n ¼ 5; PBS-injected Rosa-CTGF cKO mice, n ¼ 6; chlorhexidine gluconate (CG)-injected control mice, n ¼ 10; CG-injected Rosa-CTGF cKO mice, n ¼ 10.
Induction of peritoneal fibrosis
Peritoneal fibrosis was induced in mice at 7 weeks of age with intraperitoneal injections of 0.01 mL/gBW of 0.1% CG in 15% ethanol and 85% PBS, three times a week for 1, 2, 3 and 4 weeks as previously reported (n ¼ 5, each) [18, 19] . Control mice received intraperitoneal injection of PBS.
Peritoneal histology
Peritoneal sections were stained with Masson's trichrome and examined as described previously [18] .
Modified peritoneal equilibration test
A modified peritoneal equilibration test (PET) was conducted to determine peritoneal permeability as described previously [18] . Wild-type or Rosa-CTGF cKO mice were injected with CG (n ¼ 5, each) three times a week for 2 weeks, and then PET was performed using 3 mL 7% glucose dialysis solution. After a 2-h retention period, dialysis fluids and blood were collected.
Immunohistochemistry
Immunohistochemical studies of the peritoneal samples were performed as described previously [18, 20, 21] . Primary antibodies used were goat anti-CTGF antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), rabbit anti-CTGF antibody (Abcam, Cambridge, UK), rabbit anti-S100A4 antibody (DAKO, Glostrup, Denmark), rat anti-MAC-2 antibody (Cedarlane, Burlington, Ontario, Canada), rat anti-mouse CD31 antibody (BD Biosciences, San Jose, CA, USA), rabbit anti-VEGF antibody (Santa Cruz Biotechnology Inc.), rat antimouse Ki67 antibody (DAKO) and rat anti-rabbit aSMA antibody (Abcam).
Peritoneal RNA extraction and real-time RT-PCR
Quantitative real-time RT-PCR was performed using the StepOnePlus System (Applied Biosystems, Foster City, CA, USA) as described previously [22] . Primers and probes sequences are listed in Supplementary data, Table S1 .
Statistical analysis
Data are expressed as means 6 standard error (SE). Statistical analyses were performed using Student's t-test, the Tukey-Kramer test or Dunnett's test using JMP9 statistical software (SAS Institute, Cary, NC, USA). P-values <0.05 were considered statistically significant.
R E S U L T S
Upregulation of CTGF in peritoneal fibrosis
We investigated CTGF expression in human peritoneal biopsy samples. In these samples, CTGF expression in peritoneum obtained at the time of catheter removal was increased compared with that of catheter implantation (Supplementary data, Figure  S1 ), which was consistent with a previous report [13] .
Next, we induced peritoneal fibrosis in wild-type mice by injecting CG intraperitoneally. CG-injected mice showed marked thickening of the submesothelial peritoneal membrane compared with PBS-injected mice. CTGF was expressed mainly within the mesothelial cells and fibroblasts of the peritoneum in control mice ( Figure 1A ). Wild-type mice showed increased CTGF expression within the mesothelial cells and fibroblasts in the submesothelial area of the peritoneum at 3 weeks postinduction of peritoneal fibrosis ( Figure 1A ). Ctgf mRNA expression in the peritoneum of CG-treated mice gradually increased, eventually reaching a level eight times higher than that observed in PBS-treated mice, at 4 weeks ( Figure 1B ). Peritoneal mRNA expression of Tgfb1, Vegfa and Col1a1 in CG-treated mice was also increased, compared with expression in PBS-treated mice, at 4 weeks ( Figure 1C -E). We confirmed that CTGF was increased in human and mouse peritoneum with fibrotic changes.
Amelioration of peritoneal fibrosis in CTGF knockout mice
We examined whether deletion of CTGF could ameliorate peritoneal fibrosis using tamoxifen-inducible conditional CTGF KO (Rosa-CTGF cKO) mice. To investigate the efficacy of CTGF deletion in Rosa-CTGF cKO mice, we examined CTGF expression in the peritoneum by immunohistochemical study (Figure 2A and B) , and real-time RT-PCR analysis. Augmented peritoneal CTGF expression in CG-treated control mice was decreased in Rosa-CTGF cKO mice compared with control mice (Figure 2A and B) . Peritoneal mRNA expression of Ctgf was decreased by 99% in PBS-treated Rosa-CTGF cKO mice compared with PBS-treated control mice ( Figure 2C ). Treatment with CG enhanced Ctgf mRNA expression in the peritoneum of control mice. Peritoneal Ctgf expression decreased by 96% in Rosa-CTGF cKO mice with peritoneal fibrosis compared with control mice with peritoneal fibrosis ( Figure 2C ). To identify CTGF-producing cells in peritoneal fibrosis, we performed the double immunofluorescent study for CTGF and S100A4, a fibroblast marker. Administration of CG induced marked accumulation of CTGFþ/S100A4þ double positive cells, which were significantly reduced in Rosa-CTGF cKO mice. These results suggest that most dominant CTGF-producing cells in peritoneal fibrosis were fibroblasts ( Figure 2D ).
There were no histological changes in the peritoneum between PBS-treated control and Rosa-CTGF cKO mice ( Figure 3A) . Control mice treated with CG showed marked thickening of the peritoneum ( Figure 3A) . In contrast, CGtreated Rosa-CTGF cKO mice exhibited reduced thickening of peritoneum on day 28 ( Figure 3A ). Quantitative study of peritoneal thickness revealed a 55% reduction of peritoneal fibrosis in Rosa-CTGF cKO mice (control mice 471.3 lm versus Rosa-CTGF cKO mice 208.5 lm; Figure 3B ).
Fibrosis and inflammation in CTGF knockout mice
CTGF has been implicated in fibrosis and proinflammatory responses in many organs. To explore the mechanisms of amelioration in peritoneal fibrosis by CTGF deletion, we assessed fibrosis and inflammation in the peritoneum. Initially, we assessed peritoneal fibrosis by immunohistochemical study for aSMA, a myofibroblast marker. The number of aSMA-positive cells in the peritoneum was upregulated by CG treatment and was decreased in CG-injected Rosa-CTGF cKO mice compared with CG-treated control mice ( Figure 4A and B) . Cell proliferation was assessed by immunohistochemical study for Ki67. The number of Ki67-positive cells in the peritoneum was decreased in CG-injected Rosa-CTGF cKO mice compared with CGtreated control mice ( Figure 4C and D) . Next, we assessed double immunofluorescent study for aSMA and Ki67 to confirm that the myofibroblasts were indeed proliferating. Most of the Ki67-positive cells in the peritoneum of CG-treated control mice were also positive for aSMA and these double positive cells were decreased in Rosa-CTGF cKO mice ( Figure 4E Figure 4G ), indicating reduction of myofibroblasts of the peritoneum in Rosa-CTGF cKO mice.
Macrophage infiltration was a prominent feature of peritoneal fibrosis. The degree of macrophage accumulation in the submesothelial area was decreased in CG-injected Rosa-CTGF cKO mice compared with CG-treated control mice on MAC-2 immunostaining ( Figure 5A and B) . Peritoneal mRNA expression of Cd68 was also decreased in Rosa-CTGF cKO mice with peritoneal fibrosis ( Figure 5C ). Ccl2 mRNA expression tended to decrease in Rosa-CTGF cKO mice ( Figure 5D ). These results indicate that CTGF is involved in macrophage accumulation and inflammation of the peritoneum.
Changes of peritoneal small-solute transport in CTGF knockout mice PET was conducted to examine the functional role of CTGF on peritoneal fibrosis at 2 weeks after the first CG injection. Figure 6 shows the ratio of urea and creatinine concentrations in the dialysate per serum. There were no changes in the peritoneal permeability between PBS-treated control and Rosa-CTGF cKO mice. Control mice treated with CG showed increased dialysate to plasma concentration (D/P) urea, D/P creatinine, volume of the effluent and decreased ratio of end dialysate to initial dialysate concentration (D/D0 0 ) glucose. CG-treated Rosa-CTGF cKO mice exhibited significant reduction of D/P urea compared with CG-treated control mice (control mice 0.83 versus Rosa-CTGF cKO mice 0.73; Figure 6A ). There was no significant difference in D/P creatinine between CG-treated groups ( Figure 6B ). D/D 0 glucose in CG-treated Rosa-CTGF cKO mice was higher than observed CG-treated control mice (control mice 0.28 versus Rosa-CTGF cKO mice 0.36; Figure  6C ). The volume of the effluent in CG-treated Rosa-CTGF cKO mice was not significantly different from observed in control mice ( Figure 6D ). These results indicate that excessive peritoneal small-solute transport was normalized by deletion of CTGF in peritoneal fibrosis.
Angiogenesis in CTGF knockout mice
In this study, Rosa-CTGF cKO mice showed improvement in peritoneal permeability on a PET. Because many studies indicated the relationship of angiogenesis to peritoneal permeability, we focused on the effect of CTGF on angiogenesis in peritoneal fibrosis by immunohistochemical study for CD31, a marker for endothelial cells. The number of CD31-positive vessels in the peritoneum was decreased in CG-injected Rosa-CTGF cKO mice compared with CG-treated control mice ( Figure 7A and B) . VEGF-A is closely involved in angiogenesis in peritoneal fibrosis [23] . Next, we performed immunohistochemical staining for VEGF. The number of VEGF-positive cells in the peritoneum was decreased in CG-injected Rosa-CTGF cKO mice compared with CG-injected control mice ( Figure 7C ). Peritoneal mRNA expression of Pecam1 and Vegfa was also decreased in Rosa-CTGF cKO mice with peritoneal fibrosis ( Figure 7D and E). These results indicate that CD31-positive vessels were increased by angiogenesis, induced by upregulation of VEGF-A in peritoneal fibrosis, and that deletion of CTGF decreased the excessive peritoneal permeability by reducing angiogenesis.
D I S C U S S I O N
In this study, we confirmed that the CTGF expression in the mesothelial cells and fibroblasts of the peritoneum was upregulated in mice with peritoneal fibrosis induced by intraperitoneal CG injection [11, 23] . In the progression of peritoneal damage, both the fibrotic and the inflammatory processes are involved [24] . The link between these two processes is frequently bidirectional, with each one influencing the other [25] . CTGF proteins are increased, by disease, in organs such as kidneys, liver and lungs, potentially resulting in fibrosis, inflammation and angiogenesis [22, 26, 27] . Therapeutic targeting of CTGF may be potential treatment for peritoneal fibrosis. Although deletion or blockade of CTGF can ameliorate renal fibrosis [15, 20] , the effects of CTGF inhibition in peritoneal fibrosis were elusive. In this study, we showed the effects of CTGF inhibition in peritoneal fibrosis by using drug-inducible CTGF KO mice. Although almost all CTGF could be deleted in Rosa-CTGF cKO mice, ablation of CTGF did not affect peritoneal structure in PBStreated CTGF cKO mice at the basal level. After inducing peritoneal fibrosis by intraperitoneal injection of CG, CTGF cKO mice exhibited reduced thickening of peritoneum, compared with CG-treated control mice. These results confirm that CTGF plays an important role in peritoneal fibrosis. However, although CTGF was deleted almost completely, peritoneal fibrosis was reduced only by 55%, suggesting the CTGFindependent pathway. In fact, the CG model exhibits peritoneal fibrosis with augmentation of many growth factors and cytokines including TGF-b, VEGF [28] , epidermal growth factor [29] and cytotoxic T-lymphocyte associated antigen 4. As CTGF is a downstream mediator of TGF-b signalling, inhibition of CTGF will inhibit TGF-b-induced peritoneal fibrosis. In this study, we demonstrate that CG-treated Rosa-CTGF cKO mice exhibited almost 50% reduction of MAC-2-positive cell infiltration and Cd68 mRNA expression, suggesting contribution of an inflammation-dependent pathway as a CTGFindependent mechanism.
The proliferation of myofibroblasts in the submesothelial area, along with the loss of mesothelial cells, are characteristic changes in peritoneal fibrosis. The origin of myofibroblasts is reported to be mesothelial cells by epithelial mesenchymal transition (EMT), resident fibroblasts and bone marrowderived cells [30, 31] , and this issue remains controversial.
CTGF is closely associated with formation of myofibroblasts [11] . A previous report showed that CTGF deletion in fibroblasts ameliorated bleomycin-induced skin fibrosis [32] . The authors concluded that fibroblast-specific CTGF KO mice would be unable to recruit myofibroblasts to the site of fibrosis. In this study, CTGF cKO mice showed reduced accumulation of aSMA-and Ki67-positive cells in the submesothelial area, compared with control mice with peritoneal fibrosis. A previous report showed that CTGF induced EMT in peritoneal mesothelial cells [33] . Taken together, these results indicate that CTGF in the peritoneum, especially in fibroblasts, also affects myofibroblast recruitment and proliferation or that CTGF may play an important role in EMT, although we could not show direct evidence of CTGF-induced EMT in this study. In addition, Xiao et al. indicated CTGF knockdown in HPMC downregulates ECM protein and Vegfa expression induced by TGF-b [34] .
Excessive peritoneal small-solute transport examined by a PET in CG-treated control mice was reduced in CG-treated Rosa-CTGF cKO mice, suggesting that CTGF increases peritoneal small-solute transport in the setting of peritoneal fibrosis. Increase in small-solute transport is closely associated with ultrafiltration failure [35] . This study showed that the ratio of net ultrafiltration to body weight in CG-treated Rosa-CTGF cKO mice was slightly increased, but not significantly different from that observed in control mice. However, the ratio of glucose concentration at 0/2 h was increased in CG-treated Rosa CTGF cKO mice, indicating that ultrafiltration failure may be improved. PET was conducted by 7% glucose dialysate to keep effluent volume, which can estimate ultrafiltration ability in the CG model. This is the limitation of this study. There are several factors that induce increase in peritoneal permeability such as angiogenesis, lymphangiogenesis and downregulation of aquaporin 1 [36] [37] [38] . Of these, upregulation of VEGF-A causes angiogenesis with increasing capillary wall permeability and small-solute transport in peritoneal membrane, ultimately causing ultrafiltration failure [23] . Previous reports showed that CTGF induces angiogenesis by activating VEGF-A in endothelial cells [39] . In this study, peritoneal VEGF-A and CD31 was decreased in CG-treated Rosa-CTGF cKO mice compared with CG-treated control mice. These results indicate that deletion of CTGF can inhibit angiogenesis in peritoneal fibrosis. Morelle et al. [40] showed that vascular density is well correlated with submesothelial thickness.
In this study, we used tamoxifen to activate Cre recombinase and delete CTGF [41] . Tamoxifen has been used to treat some fibrotic disorders and several studies have confirmed the effectiveness of tamoxifen in the treatment of EPS [42, 43] . Using an animal model, Huang et al. [44] reported that tamoxifen can ameliorate peritoneal fibrosis by inhibiting CTGF in mice. In this study, tamoxifen acts in a similar manner in both control and CTGF cKO mice. When compared with previous reports showing CG-treatment without tamoxifen, CG-treated control mice in this study showed similar peritoneal fibrosis and function.
In the present study, we induced peritoneal fibrosis after CTGF deletion. The effects of CTGF deletion after induction of peritoneal fibrosis are unknown. CTGF upregulation in peritoneal damage models is known to occur not only in the CG model, but also in PD solution or mechanical scraping. As CTGF is a common mediator of fibrosis, inhibition of CTGF could have the potential to ameliorate peritoneal fibrosis in these models [45, 46] . Further studies are needed to show the mechanisms by which deletion of CTGF potentially ameliorates peritoneal fibrosis. In clinical settings, CTGF levels in dialysate correlate well with duration of PD and D/P creatinine, and CTGF expression in the peritoneum is increased in mesothelial cells and fibroblast-like cells at the removal of the catheter, consistent with our results [13] . Our finding in the human biopsy samples in this study is limited because samples were taken in the vicinity of the catheter insertion site. Levels of CTGF in the dialysate of patients with EPS were significantly higher than those found in patients without EPS [12] .
CTGF is closely associated with inflammation. CTGF induces chemokines and adhesion molecules associated with the recruitment of inflammatory cells [47] . Among these, Ccl2 is a major chemokine concerning macrophage infiltration [48] . In the present study, we demonstrated upregulation of Ccl2 and accumulation of macrophages in CG-treated mice. CG-treated Rosa-CTGF cKO mice exhibited reduction of macrophage infiltration in the peritoneum, indicating that CTGF is involved in macrophage infiltration. Further evaluation is necessary to determine what molecules are important in amelioration of macrophage infiltration by CTGF deletion.
A phase 2 clinical trial was conducted to assess the safety and efficacy of FG-3019, an anti-CTGF monoclonal antibody, on idiopathic pulmonary fibrosis. FG-3019 was shown to be safe in human diseases [49] . Recently, Sakai et al. [50] reported inhibition of CTGF by using FG-3019 can ameliorate peritoneal fibrosis through suppression of myofibroblast accumulation and angiogenesis, suggesting that FG-3019 could be useful in the treatment of peritoneal fibrosis. These results supported our result that deletion of CTGF in cKO mice ameliorates peritoneal fibrosis and angiogenesis. In addition, we unveil novel findings in this study that CTGF increases peritoneal smallsolute transport in peritoneal damage by using mice model with 96% reduction of CTGF.
In conclusion, systemic deletion of CTGF can ameliorate peritoneal fibrosis by suppressing fibrosis, inflammation and angiogenesis. Deletion of CTGF also ameliorates excessive peritoneal small-solute transport in peritoneal damage. These findings demonstrate the importance of CTGF in peritoneal transformation, inflammation and fibrosis, and support further examination of CTGF as a potential target for the treatment of peritoneal damage. 
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